3 Other information

3.1 Scope and how this guideline was developed

NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover.

How this guideline was developed

NICE commissioned the National Collaborating Centre for Cancer to develop this guideline. The Centre established a Guideline Development Group (see section 4), which reviewed the evidence and developed the recommendations.

The methods and processes for developing NICE clinical guidelines are described in the guidelines manual.

3.2 Related NICE guidance

Further information is available on the NICE website.

Published

General

Under development

NICE is developing the following guidance:

  • Sunlight exposure: communicating the benefits and risks to the general public. NICE guideline. Publication expected September 2015.

  • Skin cancer: the VivaScope 1500 and 3000 systems for detecting and monitoring skin lesions. NICE diagnostics guidance. Publication expected November 2015.

  • Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab. NICE technology appraisal guidance. Publication expected December 2015.

  • Dabrafenib and trametinib for treating advanced unresectable or metastatic BRAFV600 mutation‑positive melanoma. NICE technology appraisal guidance. Publication expected August 2016.

  • Ipilimumab for the adjuvant treatment of completely resected high risk stage III or IV melanoma. NICE technology appraisal guidance. Publication date to be confirmed.

  • National Institute for Health and Care Excellence (NICE)